We studied the predictive performance of the Minto pharmacokinetic model during cardiopulmonary bypass in patients undergoing cardiac surgery. Patients received remifentanil target-controlled infusion using the Minto model during total intravenous anaesthesia with propofol. From 56 patients, 275 arterial blood samples were drawn before, during and after bypass to determine the plasma concentration of remifentanil, and the predicted concentrations were recorded at each time. For pooled data, the median prediction error and median absolute prediction error were 21.3% and 21.8%, respectively, and 22.1% and 22.3% during bypass. Both were 148.4% during hypothermic circulatory arrest and measured concentrations were more than three times greater than predicted (26.9 (17.0) vs. 7.1 (1.6) ng.ml À1 ). The Minto model showed considerable bias but overall acceptable precision during bypass. The target concentration of remifentanil should be reduced when using the Minto model during hypothermic circulatory arrest.
Introduction
Remifentanil is a widely used, l-receptor opioid agonist [1] often administered by target-controlled infusion (TCI). It is easy to titrate due to its rapid onset and offset, and short context-sensitive half-time [2] . There are several pharmacokinetic (PK) models for remifentanil TCI [3] [4] [5] [6] [7] . Among these, the Minto model has acceptable predictive performance during non-cardiac surgery [8] . Drug disposition and action can be altered during cardiopulmonary bypass due to haemodilution, hypothermia, pH changes and altered protein binding [9] . The PK properties can also be affected by bypass [10] . Our primary study goal was to evaluate whether the predictive performance of the Minto model is clinically acceptable in patients undergoing cardiac surgery on bypass. In addition, the effects of bypass may differ between commercial drugs due to possible differences in bio-equivalence [11, 12] . Thus, we compared the performance of two formulations of remifentanil, Ultiva â (GlaxoSmithKline, Mid-
Methods
The study was approved by the institutional review board of Seoul National University Hospital. All participants provided written informed consent. The study was performed according to Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. ASA physical status 1-3 adults (20-80 years) undergoing cardiac surgery using bypass were screened for eligibility. Patients who were drug abusers, using pre-operative opioids or pregnant were not studied. After providing written, informed consent, patients were randomly assigned to receive Ultiva or Remiva. Block randomisation (blocks of four or six) was performed using a computer-generated randomisation program. An independent physician not involved in the study conducted randomisation in a 1:1 ratio and concealed it in opaque envelopes. The group assignment was blinded to patients, anaesthesia providers and investigators. Without premedication, patients were monitored with five-lead electrocardiography, pulse oximetry, non-invasive blood pressure (Solar 8000M and remifentanil. Sealed randomisation envelopes were given to an independent research nurse, who was not involved in data analyses. The anaesthetist in charge contacted the research nurse to prepare the allocated Ultiva or Remiva, which were prepared in identical syringes, marked with the name of the patient and the study registration number. For TCI, the effect-site concentration was set to 5-15 ng.ml À1 for remifentanil using the Minto model, and 1-4 lg.ml À1 for propofol using the Marsh model, with a commercial infusion pump (Orchestra, Fresenius Vial, Brezins, France). The bispectral index was kept below 60. The target concentration of remifentanil was titrated according to each patient's haemodynamic changes and surgical conditions. Nasopharyngeal and rectal temperatures were monitored. Crystalloid (Plasma Solution A, CJ HealthCare, Seoul, South Korea) was used for maintenance fluid and blood products were transfused to maintain haematocrit > 27-30% with consideration of surgical bleeding, haemodynamic monitoring and underlying comorbidities.
The bypass circuit incorporating a membrane oxygenator was primed with 1-1.5 l of lactated Ringer's solution, 300 ml 15% mannitol, 100 ml 20% albumin, sodium bicarbonate and heparin. Non-pulsatile bypass was performed (Advanced Perfusion System 1, Terumo Cardiovascular Systems Corporation, Ann Arbor, MI, USA) with a pump flow of 2-2.5 l.min
À1
.m À2 of body surface area and a-stat pH management was used under moderate hypothermia (23-29°C). Hypothermic circulatory arrest was performed with selective cerebral perfusion under core temperatures of less than 25°C if indicated. During bypass, mean arterial pressure was maintained between 50 and 80 mmHg, and haematocrit was targeted to be 20-25%. Intra-operative cell salvage was performed and myocardial protection was supported by antegrade or retrograde cold-blood cardioplegia. Initial heparinisation was achieved by administering intravenous (i.v.) heparin 3 mg.kg À1 to maintain an activated clotting time > 400 s during bypass. Heparinisation was reversed by protamine after weaning from bypass. Arterial blood samples to measure plasma concentration of remifentanil were taken before bypass (at 1 h after induction of anaesthesia), after 30 min, 60 min and 90 min of bypass, and at the completion of bypass (1 h after infusion of protamine). For each patient, samples were taken at least 5 min after any changes in the target concentrations and after equilibrium of the plasma and effect-site concentrations were displayed. At each time-point, the predicted plasma concentration by the Minto model was also recorded. Blood samples were collected in tubes containing heparin sodium and were immediately centrifuged (3515 g, 15 min, 4°C) to separate plasma. Formic acid was added (1.5 ll 100% formic acid per 1 ml plasma) before freezing at À70°C to inhibit the activity of esterase. The plasma concentration was determined based on tandem mass spectrometry detection (API 4000 Q-TRAP mass spectrometer, AB SCIEX, Framingham, MA, USA) with a quantification limit of 0.1 ng.ml
. The intra-assay coefficients of variation at plasma concentrations of 0.1 ng.ml À1 , 0.3 ng.ml À1 , 15 ng.ml À1 and 75 ng.ml À1 were 6.89%, 7.32%, 1.87% and 2.58%, respectively. The corresponding inter-assay coefficients of variation were 5.10%, 5.46%, 5.24% and 5.21%, respectively. The predictive performance of the model was evaluated by calculating percentage prediction errors (PE) according to the methods previously described [13] . For each sample the PE was calculated as:
where Cm ij is the measured plasma concentration in sample j from patient i, and Cp ij is the predicted concentration in that sample. The series of PEs were then used to calculate, for each patient and for the entire group, the median of the PE (MDPE) and absolute PE (MDAPE). Median prediction error represents the intrasubject bias of the predicted concentration compared with the measured one. Median absolute prediction error reflects the precision of the system. It has been suggested that the performance of a typical TCI model is clinically acceptable if MDPE is between À20% and 20%, and MDAPE is < 30% [14] . In a previous study, the MDPE of the Minto model during general anaesthesia was À15% (95%CI, À17% to À12%) [8] . To detect a difference of 40% in MDPE, which was considered to be clinically significant, we calculated that 50 patients would be required with five samples per patient with 0.1 intrasubject correlations, at a two-sided significance level of 5% and power of 80%. Considering a 10% of dropout rate, a total of 56 patients were estimated.
The normality of data was checked using the Kolmogorov-Smirnov and Shapiro-Wilk tests.
Comparisons were conducted using Student's t-test, the Mann-Whitney U-test, Pearson's chi-square test and Fisher's exact test. Serial changes in repeatedly measured values were analysed using linear mixed models. In the mixed model, group, time and the interaction between group and time were regarded as fixed effects, and subject was regarded as a random effect. Residuals vs. fitted values plots were used to check that the error terms (residuals) had a mean of zero and constant variance. The normality assumption for the model residuals was checked with histograms and normal quantilequantile plots of residuals, which seemed to be normally distributed. For multiple testing, p values were adjusted using the Hochberg method. Analyses were performed using SPSS (ver. 21.0.0.0, IBM, Armonk, NY, USA) and SAS software (ver. 9.2, SAS institute, Cary, NC, USA). In all analyses, p values < 0.05 were considered to indicate statistical significance.
Results
Between January and May 2016, 61 patients were screened. Patients who were not eligible were not studied, 56 patients received Ultiva or Remiva (28 each; Fig. 1 ). Baseline patient characteristics and operative variables are shown in Tables 1 and 2 . Six patients underwent circulatory arrest. During circulatory arrest, core temperatures were significantly lower than those during other bypass times (21.6 (2.1)°C vs. 29.1 (3.8)°C for nasopharyngeal temperature, p < 0.001 and 25.0 (3.9)°C vs. 30.0 (2.4)°C for rectal temperature, p < 0.001). More patients in the Ultiva group received double valve replacements or combined surgery, and six of them underwent circulatory arrest, whereas none in the Remiva group did ( Table 2 ). The duration of bypass was longer and nadir rectal temperature was lower in the Ultiva group than in the Remiva group (Table 2) . Other peri-operative variables did not differ between the groups, except for temperatures at 60 min and 90 min of bypass (Table 3) . Increasing body temperature to wean from bypass was started in 28 patients within 60 min (n = 4 and n = 7 in the Ultiva and Remiva groups, p = 0.313) or 90 min (n = 11 and n = 17 in the Ultiva and Remiva groups, p = 0.016).
In total, 275 blood samples were obtained and analysed (138 for Ultiva and 137 for Remiva). During bypass, 168 blood samples were obtained and analysed (84 in each group). The measured concentrations were generally higher than predicted, particularly when the samples under circulatory arrest were included (Figs. 2a  and 
Discussion
Cardiopulmonary bypass provides a technically accessible operative field while maintaining major organ perfusion during cardiac surgery. However, the PK of i.v. opioids has been shown to be affected by bypass [15] . When administered by constant infusion, the plasma concentration of fentanyl decreased (average 30%) on commencing bypass, and then returned to pre-bypass levels within 30 min [16] . No relationship between temperature and fentanyl concentration has been observed [17] . The total concentration of alfentanil decreased by 60% with the onset of bypass during a constant infusion, and the authors suggested that this could be attributed to haemodilution [18] . When being infused at a variable rate, plasma sufentanil concentrations decreased by 30-55% at the beginning of bypass and then increased during rewarming, indicating the tissue sequestration of sufentanil [19] . However, during bypass, the sufentanil concentration increased and there appeared to be an inverse relationship between temperatures and drug concentrations, suggesting decreased drug metabolism during hypothermia [17, 20] .
Regarding TCI models, the Gepts model for sufentanil had significant overprediction (MDPE, À42.1%) and inaccuracy (MDAPE, 40.9%) during and after bypass with moderate hypothermia [21] . On the other hand, the model showed clinically acceptable performance (MDPE, 3.9%) during normothermic bypass in patients having coronary artery bypass [22] . However, there was a significant underprediction (MDPE, 59.6%) in the pre-bypass period in that study. During mild hypothermic (28-32°C) or normothermic bypass, the temperature is not a significant factor affecting drug clearance [22, 23] . In experiments using a series of different temperatures (34°C, 37°C and 41°C), increasing temperature induced quicker clearance of remifentanil in the presence of porcine liver esterase [24] . The elimination clearance of remifentanil decreased by 6.37% for each degree Celsius decrease in temperature below 37°C [25] . This reduction in clearance may be attributable to reduced enzymatic hydrolysis activity induced by the effects of hypothermia on blood and tissue esterases [10] . Consistently, the measured concentration of remifentanil under hypothermic (mean, 28.5°C) bypass was higher than predicted in this study. Moreover, samples during circulatory arrest (mean, 21.6°C) had greater bias and inaccuracy than during bypass but not with circulatory arrest (mean, 29.1°C). During circulatory arrest, blood circulation is quite different from the normal physiological state and even from that during bypass. In this study, only the right subclavian artery or carotid arteries were perfused for cerebral perfusion with a low flow (200-800 ml.min À1 ), and other parts of the body were not perfused during circulatory arrest. Considering such differences in circulation between circulatory arrest and the normal physiological status from which the model was established, it might be reasonable to expect that the model would not work well during circulatory arrest. Moreover, there is a difference in the proteomic milieu between circulatory arrest and bypass: levels of intestinal fatty acid-binding protein are significantly higher in the plasma during circulatory arrest than during bypass [26] . The activity of the complement system is also lower during deep hypothermic circulatory arrest than during normothermic bypass [27] . Thus, the greater bias and inaccuracy during circulatory arrest than during bypass in this study can be partly explained by altered enzymatic hydrolysis activity, which might be affected by the more profound hypothermia during circulatory arrest.
Although one study has suggested that high doses of remifentanil produce brain damage and mortality in rats [28] , more recent investigators have reported opioid-mediated neuroprotection and cardioprotection in both animal and clinical studies [29, 30] . Morphineinduced activation of the l-opioid receptor attenuated neurotoxicity in cultured cortical neurons [31] , and remifentanil preconditioning reduced infarct size of the isolated rat heart [32] . In this study, we had higher plasma concentration of remifentanil than predicted during bypass and circulatory arrest. However, as we did not evaluate organ protection, it is hard to draw any conclusion whether higher concentrations of remifentanil had any benefit or adverse effect. We observed significant bias and inaccuracy of the model before bypass. This may, in part, be explained by the un-equilibrated status of patients following anaesthesia induction. Although each sampling was achieved during stable haemodynamics and in the absence of recent changes in concentrations, unpredicted PK variables could have changed in the early anaesthesia period [33] . The poor predictive performance of PK models in the early anaesthetic period has also been observed previously. The mean PE of the Marsh model for propofol was 51.6% up to 30 min after induction during neurosurgery [33] . The Gepts model for sufentanil had a MDPE of 59.6% in the pre-bypass period in cardiac surgery [22] . However, the number of samples before bypass was fewer than those during bypass, and this might have influenced the results. Similarly, previous authors reported better predictive performance of a TCI model using sufentanil in the (pre-bypass) period when more samples were extracted than in other (during and after bypass) periods (six vs. two samples each), and discussed it as one of the limitations of their study [21] . Moreover, the study subjects were patients undergoing cardiac surgery in this study. Thus, population effects might have influenced the predictive performance the Minto model originally developed from volunteers.
We used two preparations of remifentanil. Although the bias and inaccuracy were lower with Remiva than with Ultiva, the influence of circulatory arrest, included only in the Ultiva group, could have been the main reason for the difference. Hypothermic circulatory arrest itself may have caused the longer bypass times and the lower nadir core temperature. In the context of the effects of hypothermia on altered elimination clearance, it is hard to draw any conclusion Table 3 Concentration of remifentanil and peri-operative parameters during cardiac surgery using cardiopulmonary bypass (CPB). Values are mean (SD). Interaction between time and group was significant for nasopharyngeal temperature (p = 0.005) and rectal temperature (p = 0.001); and not significant for mean arterial pressure (p = 0.657), bispectral index (p = 0.943), pH (p = 0.709) and haematocrit (p = 0.561).
Group
Before CPB CPB 30 min CPB 60 min CPB 90 min After CPB as to whether either formulation would be more suitable for the model from these results. This study has some limitations. First, we did not evaluate the effects of bypass on any change in volume of distribution or other variables that could have explained the PK properties of remifentanil during bypass, based on compartment models. However, this was beyond of the scope of the present study, and may be evaluated in future investigations. Second, as mentioned above, the number of samples was limited to fully evaluate the performance of the model before or after the bypass period. As we focused on the effects of bypass, the results during the pre-bypass and postbypass periods should be cautiously interpreted. Finally, we did not consider circulatory arrest to be a significant factor before patient recruitment. Although randomised, circulatory arrest cases were included only in the Ultiva group, which were suspected to have affected the performance of the model.
In conclusion, the Minto model had considerable bias but overall acceptable precision during moderate hypothermic bypass in patients undergoing cardiac surgery. During hypothermic circulatory arrest, the model had much greater bias and less precision. The target concentration of remifentanil should be reduced CPB, cardiopulmonary bypass; HCA, hypothermic circulatory arrest; MDPE, median prediction error; MDAPE, median absolute prediction error.
when using the Minto model during hypothermic circulatory arrest in cardiac surgery.
